Respiratory syncytial virus (RSV) is a common viral infection and is known to be a leading cause of lower respiratory tract infections in older adults. Recent vaccine approvals by the FDA now provide vaccination options for this select population. During this session, we will explore the basics on RSV and review vaccine strategies in older adults. The session will also cover clinical data from on-going trials for FDA-approved RSV vaccines and those that are still being studied.